Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Income (2016 - 2024)

Seres Therapeutics (MCRB) has disclosed Net Income for 10 consecutive years, with $139.8 million as the latest value for Q3 2024.

  • Quarterly Net Income rose 2144.32% to $139.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $139.8 million through Jun 2025, up 612.62% year-over-year, with the annual reading at $125.9 million for FY2024, 64.79% up from the prior year.
  • Net Income hit $139.8 million in Q3 2024 for Seres Therapeutics, up from -$6.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $139.8 million in Q3 2024 to a low of -$71.5 million in Q1 2023.
  • Historically, Net Income has averaged -$13.1 million across 5 years, with a median of -$20.2 million in 2020.
  • Biggest five-year swings in Net Income: tumbled 197.27% in 2023 and later skyrocketed 2144.32% in 2024.
  • Year by year, Net Income stood at -$18.0 million in 2020, then crashed by 175.35% to -$49.7 million in 2021, then soared by 95.58% to -$2.2 million in 2022, then crashed by 197.27% to -$6.5 million in 2023, then skyrocketed by 2240.73% to $139.8 million in 2024.
  • Business Quant data shows Net Income for MCRB at $139.8 million in Q3 2024, -$6.7 million in Q2 2024, and -$7.2 million in Q1 2024.